Gefitinib induced erythema multiforme infection with ulcer and wound treatment:a case report
YAO Xiuqiu
YANG Shuling
MO Peimiao
WU Yongfang
Abstract：Gefitinib is a selective epidermal growth factor receptor (epithelial growth factor receptor, EGFR) tyrosine kinase inhibitor, a molecular targeted anticancer drug, mainly used to treat patients with locally advanced or metastatic non-small cell lung cancer (non-small cell lung cancer, NSCLC) who have previously received chemotherapy [1]. Erythema multiforme infection and ulcer caused by gefitinib is a rare adverse reaction with no relevant treatment references. Since November 2022, the Department of Wound Repair, Burn, Plastic and Cosmetic Surgery, Baise People's Hospital treated one patient with erythema multiforme infection and ulcer caused by gefitinib, and the wound healed well. The following is a report.
Keywords：GefitinibErythema multiforme infection with ulcerWound treatmentWet healing
Publication Date：2025-04-15
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：2( 256,后插1 )